Glycobiology of the Immune System and Disease

1. Glycans of the immune system
(i) Immune system
(ii) Glycans
(iii) Glycosylation
(iv) Glycan-binding proteins (GBPs) or lectins

2. C-type lectin in host-pathogen interactions
(i) structure
(ii) C-type lectin receptors and infection biology

3.Galectins
(i) introduction
(ii) role in infection

4. Siglecs and the immune system
(i) Sialic acid recognition by siglecs and cis interactions with endogeneous glycans
(ii) Sialoadhesin and cellular interactions in the immune System

5. CD22 and B cell signalling

6. New CD33-related Siglecs in the innate immune System.

7. Modulation of Immune Tolerance by Siglec-sialic acid interaction

8. Siglecs and immune regulation
(i) Pathogen Internalization by Innate Immune Cells: Phagocytosis and Endocytosis by Siglec

9. Siglecs and the Attenuation of Inflammatory Responses
(i) Immune Evasion by Pathogens via Siglec Ligation
(ii) Attenuation of DAMP-Mediated Inflammation by Siglecs

10. The Regulation of the Life Span of Myeloid Cells in the Context of Inflammation by Siglec-8, Siglec-9, and Siglec-F
(i) Regulation of Natural Killer Cell Function by Siglec-7

11.Siglecs, Dendritic cells, and T cell activation
(i) Siglecs and the Regulation of Plasmacytoid Dendritic Cell Function
(ii) Siglecs in Conventional Dendritic Cells and the Regulation of T Cell Activation and Polarization
(iii) A Direct Role for Siglecs in T Cells
(iv) Siglecs in B Cell Biology and the Maintenance of Immunological Tolerance

12. Glycobiology of autoimmunity and chronic inflammation

13. Immune response and glycobiology
(i) Glycobiology of pathogens
(ii) role of glycan-binding proteins

14. Glycobiology of fungus and infection
(i) pathogenic fungi
(ii) Candida albicans Glycans Are Central in Host Interactions
(iii) Aspergillus fumigates
(iv) Crystococcus neoformans and its capsule
(v) Fungal glycans and drug targets

15. Glycobiology of virus and infection
(i) Zika virus
(ii) Coronavirus and COVID-19
(iii) Lassa
(iv) Mumps
(v) Chlorella
(vi) Varicella zoster
(vii) Avian coronavirus
(viii) Influenza A virus
(ix) Chikungunya virus
(x) Semliki Forest virus
(xi) Herpes simplex virus (HSV)
(xii) Rabies virus
(xiii) Rotavirus
(xiv)Ross river virus
(xv) H1N1/ H5N1 virus
(xvi) Mumps
(xvii) New Castle disease virus

16. Glycans as antibody epitopes

17. Glycobiology of bacteria and infection
(i) Bacterial surface glycans as virulence factors
(a) Polysaccharide Capsules
(b) Lipopolysaccharide (LPS)
(ii) Mechanisms of colonization and invasion
(a) Adhesins and Receptors
(b) Invasion Factors
(iii) Bacterial toxins as glycosyltransferases
(iv) Glycan based interaction of host and gut microflora: commensals and pathogens

18. Glycobiology of tumour and immunity
(i) Glycosylation in Cancer
(a) Altered branching and fucosylation of N-Glycans
(b) Increased mucins and truncated O-glycans
(c) Increased and aberrant sialic acid expression
(d) Increased selectin ligand expression
(ii) Altered expression of blood groups
(iii) Altered expression of glycospingolipids
(iv)Loss of GPI-anchor expression
(v) Altered Hyaluronan
(vi) Altered in sulfated glycosaminoglycans
(vii)Altered cytoplasmic and nuclear O-GlcNAc
(viii) Mechanisms of altered glycan expression
(ix) Glycan changes in Cancer stem cells and during EMT
(x)Clinical significance

19. Therapeutic strategies based on microorganism and virus protein-glycan interactions
(i) Structure–function considerations of glycans
(ii) Pharmacological driving force: protein–GAG interactions and the glycan-protein network (GPN)
(iii) Identification of protein-specific GAG sequences
(iv) Therapeutic approaches